Treatment Outcomes of Well-Differentiated High-Grade Neuroendocrine Tumors.

CONCLUSIONS: Among NET G3 patients, CAPTEM was the most commonly used treatment with clinically meaningful efficacy and disease control. FOLFOX or PRRT are other potentially active treatment options. EP has some activity in NET G3 but responses appear to be short-lived. Prospective studies evaluating different treatments effects in NET G3 patients are needed to determine an optimal treatment strategy. IMPLICATIONS FOR PRACTICE: High-grade well differentiated neuroendocrine tumors (NET G3) are considered different entity from low-grade NET and neuroendocrine carcinoma in terms of prognosis and management. The oral combination of capecitabine and temozolomide (CAPTEM) is considered a good option in the management of metastatic NET G3 and may be preferred. FOLFOX is another systemic option with reasonable efficacy. Similar to other well-differentiated NET, PRRT seems to have some efficacy in these tumors. PMID: 33496040 [PubMed - as supplied by publisher]
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research